Telemus Capital Lowered Its Regeneron Pharmaceutical (REGN) Position as Stock Value Declined; As Baidu (BIDU) Share Value Declined, Holder Cortland Associates Has Trimmed Its Position by $4.70 Million

April 23, 2018 - By Peter Erickson

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Cortland Associates Inc decreased its stake in Baidu Inc (BIDU) by 13.7% based on its latest 2017Q4 regulatory filing with the SEC. Cortland Associates Inc sold 20,078 shares as the company’s stock declined 3.38% with the market. The institutional investor held 126,528 shares of the technology company at the end of 2017Q4, valued at $29.63M, down from 146,606 at the end of the previous reported quarter. Cortland Associates Inc who had been investing in Baidu Inc for a number of months, seems to be less bullish one the $80.95 billion market cap company. The stock decreased 1.94% or $4.61 during the last trading session, reaching $232.5. About 2.28 million shares traded. Baidu, Inc. (NASDAQ:BIDU) has risen 36.72% since April 23, 2017 and is uptrending. It has outperformed by 25.17% the S&P500.

Telemus Capital Llc decreased its stake in Regeneron Pharmaceutical (REGN) by 99.01% based on its latest 2017Q4 regulatory filing with the SEC. Telemus Capital Llc sold 4,004 shares as the company’s stock declined 13.59% with the market. The institutional investor held 40 shares of the health care company at the end of 2017Q4, valued at $15,000, down from 4,044 at the end of the previous reported quarter. Telemus Capital Llc who had been investing in Regeneron Pharmaceutical for a number of months, seems to be less bullish one the $33.81B market cap company. The stock decreased 0.50% or $1.58 during the last trading session, reaching $314.25. About 688,735 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since April 23, 2017 and is downtrending. It has underperformed by 25.74% the S&P500.

Among 24 analysts covering Baidu (NASDAQ:BIDU), 10 have Buy rating, 3 Sell and 11 Hold. Therefore 42% are positive. Baidu had 65 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, January 22 by Nomura. As per Friday, April 29, the company rating was upgraded by Brean Capital. Bank of America maintained Baidu, Inc. (NASDAQ:BIDU) rating on Monday, September 18. Bank of America has “Buy” rating and $263.0 target. The company was maintained on Monday, February 22 by Credit Suisse. The rating was downgraded by Pacific Crest to “Sector Weight” on Tuesday, July 28. The firm has “Outperform” rating by Credit Suisse given on Wednesday, July 20. Nomura upgraded the shares of BIDU in report on Monday, July 31 to “Buy” rating. Summit Research downgraded the stock to “Hold” rating in Wednesday, September 30 report. The stock of Baidu, Inc. (NASDAQ:BIDU) has “Buy” rating given on Friday, July 28 by Macquarie Research. The stock of Baidu, Inc. (NASDAQ:BIDU) earned “Buy” rating by Jefferies on Monday, August 31.

Cortland Associates Inc, which manages about $580.00M and $548.87 million US Long portfolio, upped its stake in Visa Inc (NYSE:V) by 17,541 shares to 514,683 shares, valued at $58.68M in 2017Q4, according to the filing. It also increased its holding in Express Scripts Hldg Co (NASDAQ:ESRX) by 22,674 shares in the quarter, for a total of 834,917 shares, and has risen its stake in Danaher Corp (NYSE:DHR).

Analysts await Baidu, Inc. (NASDAQ:BIDU) to report earnings on April, 26. They expect $1.31 earnings per share, up 98.48% or $0.65 from last year’s $0.66 per share. BIDU’s profit will be $456.09M for 44.37 P/E if the $1.31 EPS becomes a reality. After $1.90 actual earnings per share reported by Baidu, Inc. for the previous quarter, Wall Street now forecasts -31.05% negative EPS growth.

Telemus Capital Llc, which manages about $2.42B and $1.29B US Long portfolio, upped its stake in Ishares Tr (IJH) by 125,861 shares to 224,776 shares, valued at $42.66M in 2017Q4, according to the filing. It also increased its holding in Alibaba Group Hldg Ltd (NYSE:BABA) by 6,047 shares in the quarter, for a total of 30,066 shares, and has risen its stake in New Residential Invt Corp (NYSE:NRZ).

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3 before the open. They expect $5.08 EPS, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.59 million for 15.47 P/E if the $5.08 EPS becomes a reality. After $4.46 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 1 Sell and 20 Hold. Therefore 36% are positive. Regeneron Pharmaceuticals Inc. had 122 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Hold” rating by Canaccord Genuity on Wednesday, February 21. Leerink Swann maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, August 3 with “Outperform” rating. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 9. On Friday, February 9 the stock rating was upgraded by Robert W. Baird to “Outperform”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Outperform” rating by Wells Fargo on Friday, December 4. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Market Perform” rating by Bernstein on Monday, June 26. The company was maintained on Thursday, November 9 by Morgan Stanley. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 6. The company was upgraded on Tuesday, August 11 by Zacks. J.P. Morgan maintained the stock with “Hold” rating in Monday, August 14 report.

Investors sentiment is 1.17 in 2017 Q4. Its the same as in 2017Q3. It is flat, as 62 investors sold REGN shares while 161 reduced holdings. only 71 funds opened positions while 191 raised stakes. 69.17 million shares or 6.15% less from 73.70 million shares in 2017Q3 were reported. Kepos Capital Ltd Partnership holds 12,467 shares. Fjarde Ap holds 0.12% or 21,676 shares. Checchi Advisers Limited Company reported 641 shares stake. Cim Investment Mangement invested in 1,163 shares or 0.15% of the stock. Conning Incorporated holds 0.03% or 2,120 shares in its portfolio. Stratos Wealth Prtnrs Ltd accumulated 0% or 28 shares. Rhumbline Advisers has 143,223 shares for 0.11% of their portfolio. Cornerstone Capital Ltd Liability Co accumulated 0.04% or 14,483 shares. State Street has 3.32 million shares. State Of New Jersey Common Pension Fund D invested in 3,000 shares or 0% of the stock. 2,257 were accumulated by Veritable Limited Partnership. 20,000 were reported by Perceptive Ltd. Endurance Wealth Management owns 30 shares. Mason Street Advsr Limited Company reported 0.09% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Tocqueville Asset Management Lp has invested 0.04% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Since February 9, 2018, it had 0 insider purchases, and 3 selling transactions for $1.71 million activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts